MSD is paying $20 million upfront to activate an alliance with Flagship Pioneering's Quotient Therapeutics that will focus on finding new therapeutic targets in inflammatory bowel disease (IBD). The ...
MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7 billion bid to acquire Terns Pharma. The Financial Times first reported that talks between the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results